Милдронат® solution for injections

General characteristics. Structure:

Active ingredient of solution for injections: 100 mg 3-(2,2,2 trimetilgidraziniya) dihydrate propionate in 1 ml of solution. 500 mg 3-(2,2,2 trimetilgidraziniya) dihydrate propionate in 1 ampoule.

Excipient: water for injections.

The means influencing metabolic processes.

Pharmacological properties:

Pharmacodynamics. Cardioprotective, anti-hypoxemic, anti-anginal, angioprotektivny action, is a gamma butyrobetaine analog. Inhibits synthesis of a carnitine therefore products of a gamma butyrobetaine which has vazodilatiruyushchy properties increase. In the conditions of intensive exercise stresses counterbalances balance between the need of fabrics for oxygen and its delivery, interferes with accumulation in cells and fabrics of decomposition products and toxins, protecting cells from damage. Mildronate stimulates metabolic processes, increases working capacity (intellectual and physical), activates humoral and cellular immunity. In ischemic fabrics (a myocardium, a retina of an eye and a brain) Mildronate redistributes a blood stream in favor of affected areas. At acute ischemic damage of a myocardium slows down formation of a zone of a necrosis, reduces the rehabilitation period. At the phenomena of heart failure Mildronate increases contractility of a myocardium, reduces the frequency and duration of attacks of stenocardia.

Pharmacokinetics. At intake it is well soaked up. Bioavailability makes about 78%. _Cmax is reached in 1–2 h by Biotransformiruyetsya in an organism with formation of two main metabolites which are removed by kidneys. The elimination half-life — 3–6 h also depends on a dose.

Indications to use:

Mildronate is used as a part of complex therapy:
- chronic heart failure,
- Ischemic heart disease (myocardial infarction, stenocardia),
- dishormonal cardiomyopathy,
- chronic and acute disorders of cerebral circulation,
- and also an abstinence syndrome at alcoholics;

Other indications:
- the lowered working capacity,
- the postoperative period for reduction of term of rehabilitation,
- physical overstrain,
- hemophthalmia,
- thrombosis of the central vein of a retina,
- retinal apoplexies of a different etiology, an azotemic and diabetic retinitis (for parabulbar introduction),
- chronic bronchitis and bronchial asthma (as immunomodulator).

Route of administration and doses:

Mildronate is applied intravenously, intramusculary and parabulbarno.

Due to a possibility of development of exciting effect drug is recommended to be used in the first half of day.

At cardiovascular diseases as a part of complex therapy drug appoint in a dose 0.5-1 g/days intravenously (on 5-10 ml of solution for injections with concentration on 500 mg / 5 in ml), frequency rate of use of 1-2 times/days. A course of treatment - 4-6 weeks.

At disturbance of cerebral circulation in an acute phase drug is appointed intravenously on 500 mg of 1 times/days within 10 days, then pass to administration of drug inside (in the corresponding dosage form - 0.5-1 g/days). The general course of therapy - 4-6 weeks.

At vascular pathology and dystrophic diseases of a retina Mildronate enter parabulbarno on 0.5 ml of solution for injections with concentration of 500 mg / 5 ml within 10 days.

At intellectual and exercise stresses appoint intravenously 500 mg of 1 times/days. A course of treatment - 10-14 days. If necessary therapy is repeated in 2-3 weeks.

At an alcoholism drug is appointed intravenously on 500 mg of 2 times/days. A course of treatment - 7-10 days.

Features of use:

Patients at prolonged use should be careful with chronic diseases of a liver and kidneys. At a myocardial infarction is not drug of the first row.

There are no sufficient data about use ^{of Mildronata®} for children.

Safety of use of drug during pregnancy is not proved. It is not found out whether drug with mother's milk is emitted. For the period of treatment it is necessary to stop breastfeeding.

There are no data on influence of this drug on speed of response.

Side effects:

Seldom — allergic reactions (reddening, rashes, an itch, hypostasis), and also the dispeptic phenomena, tachycardia, change of the ABP, excitement.

Interaction with other medicines:

Strengthens action of koronarodilatiruyushchy means, some hypotensive drugs, cardiac glycosides. It is possible to combine with anti-anginal means, anticoagulants, antiagregant, antiarrhytmic means, diuretics, bronchial spasmolytics. In view of possible development of moderate tachycardia and arterial hypotension, it is necessary to be careful at a combination with nitroglycerine, nifedipine, alpha adrenoblockers, antihypertensives and peripheral vazodilatator.

Contraindications:

For all dosage forms:

- hypersensitivity;

- increase in intracranial pressure (at disturbance of venous outflow, intracranial tumors).

Overdose:

Cases of overdose are unknown, drug малотоксичен and does not cause side effects, patients hazardous to health.

Storage conditions:

To store ampoules in the place, dry, not available to children, at a temperature not above 25 degrees Celsius.

Issue conditions:

According to the recipe

Packaging:

On 5 ml of solution in ampoules. On 5 ampoules in a strip packaging from a polyvinyl chloride film, on 2 yacheykoy packagings in a cardboard pack.